MX2020001655A - Vacuna vph. - Google Patents

Vacuna vph.

Info

Publication number
MX2020001655A
MX2020001655A MX2020001655A MX2020001655A MX2020001655A MX 2020001655 A MX2020001655 A MX 2020001655A MX 2020001655 A MX2020001655 A MX 2020001655A MX 2020001655 A MX2020001655 A MX 2020001655A MX 2020001655 A MX2020001655 A MX 2020001655A
Authority
MX
Mexico
Prior art keywords
conserved
hpv vaccine
hpv
sequences
polypeptide
Prior art date
Application number
MX2020001655A
Other languages
English (en)
Inventor
Joshua Blight
Arturo Reyes-Sandoval
Lucy Dorrell
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2020001655A publication Critical patent/MX2020001655A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a un acido nucleico que codifica un polipeptido que comprende una pluralidad de secuencias polipeptidicas conservadas, o variantes de las mismas, en donde las secuencias conservadas se conservan a traves de uno o mas genotipos de VPH 16, 18, 31, 52, 53 y 58; y en donde el polipeptido comprende una secuencia peptidica conservada de cada una de las proteinas E1, E2, E4, E5, E6 y E7 del VPH; y vacunas, vectores virales, tratamiento y profilaxis asociados.
MX2020001655A 2017-08-16 2018-08-16 Vacuna vph. MX2020001655A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1713163.2A GB201713163D0 (en) 2017-08-16 2017-08-16 HPV vaccine
PCT/GB2018/052335 WO2019034887A1 (en) 2017-08-16 2018-08-16 HPV VACCINE

Publications (1)

Publication Number Publication Date
MX2020001655A true MX2020001655A (es) 2020-08-17

Family

ID=59895974

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001655A MX2020001655A (es) 2017-08-16 2018-08-16 Vacuna vph.

Country Status (11)

Country Link
US (2) US11179456B2 (es)
EP (1) EP3668542A1 (es)
JP (1) JP2020536489A (es)
KR (1) KR20200056384A (es)
CN (1) CN111212659B (es)
AU (1) AU2018316734A1 (es)
CA (1) CA3072536A1 (es)
GB (1) GB201713163D0 (es)
MX (1) MX2020001655A (es)
SG (1) SG11202001244SA (es)
WO (1) WO2019034887A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202043256A (zh) * 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
GB202019767D0 (en) 2020-12-15 2021-01-27 Chain Biotechnology Ltd Compostitions and methods
GB202209115D0 (en) 2022-06-21 2022-08-10 Chain Biotechnology Ltd Compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US20070014810A1 (en) * 2003-12-31 2007-01-18 Denise Baker Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
BRPI0818154A2 (pt) 2007-11-02 2020-10-06 The Johns Hopkins University composições de peptídeo de hpv de multitipo e métodos para o tratamento ou prevenção de infecção por papilomavírus humano
ES2464451T3 (es) * 2008-02-21 2014-06-02 Delphi International Operations Luxembourg S.À R.L. Inyector de fuel con una disposición de control de válvula mejorada
CN102498217A (zh) 2009-04-20 2012-06-13 阿波维塔公司 Hpv的e6蛋白的特异性抗体及其应用
US20150344529A1 (en) * 2012-12-25 2015-12-03 The Chemo-Sero-Therapeutic Research Institute Vaccine for hpv infection and/or hepatitis b comprising hpv/hbs chimeric protein as active ingredient
EA034056B1 (ru) 2013-03-12 2019-12-23 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Усовершенствованные вакцины против вируса папилломы человека и способы их применения
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection

Also Published As

Publication number Publication date
AU2018316734A1 (en) 2020-02-27
GB201713163D0 (en) 2017-09-27
EP3668542A1 (en) 2020-06-24
SG11202001244SA (en) 2020-03-30
US20200306358A1 (en) 2020-10-01
CN111212659B (zh) 2023-09-22
KR20200056384A (ko) 2020-05-22
US11179456B2 (en) 2021-11-23
US20220152189A1 (en) 2022-05-19
WO2019034887A1 (en) 2019-02-21
CN111212659A (zh) 2020-05-29
CA3072536A1 (en) 2019-02-21
JP2020536489A (ja) 2020-12-17

Similar Documents

Publication Publication Date Title
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
MX2016010649A (es) Vector de virus adeno-asociado.
PH12018501912A1 (en) Vaccine against rsv
PH12019500068A1 (en) Novel adeno-associated virus capsid proteins
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
MX2017002791A (es) Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.
MX2017012097A (es) Variantes de virus adenoasociado y métodos de uso de estas.
MX2020001655A (es) Vacuna vph.
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
NZ730802A (en) Therapeutic hpv16 vaccines
MX2018010850A (es) Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
ZA201907716B (en) Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
WO2016116905A9 (en) Cmv antigens and uses thereof
MX2019011259A (es) Adyuvante mejorado de vacuna de li.
MX2017014417A (es) Vacunas contra el dengue.
PH12018500468A1 (en) Fusion protein
PH12020500526A1 (en) Paramyxoviridae expression system
MX2019002134A (es) Nuevo paramixovirus y sus usos.
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
CL2015003242A1 (es) Virus aav/upr-plus, proteína de fusión upr-plus, método de tratamiento genético y su uso en el tratamiento enfermedades neurodegenerativas, tales como las enfermedades de parkinson y huntington, entre otras.
NZ750578A (en) Viral vaccines
NO20085201L (no) Rekombinante novirhabdoviruser og deres anvendelse